rs1805007 — MC1R R151C

Strongest "R" allele in the melanocortin-1 receptor, shifting pigment from photoprotective eumelanin to pro-oxidant pheomelanin; doubles melanoma risk and triples non-melanoma skin cancer risk per allele

See your personal result for MC1R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Pigment Switch That Raises Your Skin Cancer Risk

The melanocortin-1 receptor (MC1R) is the master switch on the surface of melanocytes that decides which type of pigment your skin produces. When UV light hits the skin, the hormone alpha-MSH (α-MSH) binds to MC1R and activates a signaling cascade that shifts pigment production toward eumelanin11 eumelanin
dark brown/black pigment; physically absorbs UV photons, protecting DNA — the body's own built-in sunscreen. The R151C variant (rs1805007) swaps an arginine for a cysteine at position 151, creating a receptor that binds α-MSH normally but fails to transmit the signal. Without that downstream cAMP cascade, melanocytes default to producing pheomelanin22 pheomelanin
red/yellow pigment; photochemically unstable and produces reactive oxygen species under UV instead.

This is the molecular basis of red hair and fair skin — but the consequences extend far beyond appearance. Pheomelanin does not just fail to protect DNA; it actively contributes to DNA damage through oxidative chemistry, and the loss of MC1R signaling also impairs the cell's capacity to repair UV-induced lesions.

The Mechanism

The R151C substitution is classed as an "R" (high-penetrance, red hair color) allele because it nearly abolishes receptor function, in contrast to lower-penetrance "r" alleles that merely reduce it. In vitro, R151C retains normal α-MSH binding but generates negligible intracellular cAMP compared to wild-type MC1R. With cAMP signaling suppressed, MITF (microphthalmia-associated transcription factor) is not activated, and the downstream enzymes that produce dark eumelanin (tyrosinase, TRP1, TRP2) remain at low levels.

Pheomelanin is not merely a passive bystander. It is photochemically unstable and generates reactive oxygen species (ROS) on UV exposure33 generates reactive oxygen species (ROS) on UV exposure
amplifies UVA-induced oxidative damage including 8-oxoguanine lesions. Critically, pheomelanin synthesis also depletes glutathione — the cell's main antioxidant buffer — leaving melanocytes with reduced capacity to neutralize ROS regardless of sun exposure. Mouse experiments published in Nature44 Nature
Mitra et al. 2012 showed pheomelanin drives melanoma even without UV radiation, through oxidative DNA and lipid damage confirmed a UV-independent carcinogenic pathway: mice with pheomelanin synthesis developed melanoma at high rates even in the absence of UV exposure.

Beyond pigmentation, functional MC1R normally enhances nucleotide excision repair (NER) and base excision repair (BER) of UV-damaged DNA by upregulating XPA, XPC, OGG1, and APE-1 repair enzymes. R151C carriers lose this repair-boosting effect, compounding the damage from both UV and oxidative stress.

The Evidence

Melanoma risk: R151C is the single MC1R variant with the highest population-attributable fraction for melanoma. A meta-analysis of 20 analytic studies across 25 populations55 meta-analysis of 20 analytic studies across 25 populations
Williams et al. 2011, International Journal of Cancer; PMID 21128237 estimated the PAF at 6.28% — meaning this one variant accounts for more than 6% of all melanoma cases at the population level. Per-allele odds ratios for R151C across large studies range from 2.33 to 2.57, and homozygous TT carriers face approximately 4–6-fold elevated risk. Importantly, the risk is only partially mediated by the fair skin phenotype66 only partially mediated by the fair skin phenotype
R151C increased melanoma risk even after statistical correction for its effect on skin type, suggesting UV-independent pathways.

Mutation burden: A landmark Nature Communications study77 Nature Communications study
Robles-Espinoza et al. 2016, n=405 melanoma genomes from TCGA and Yale cohorts; PMID 27403562 found that MC1R R allele carriers showed a 42% increase in expected C→T somatic mutations compared to wild-type carriers — equivalent to an additional 21 years of UV-accumulated DNA damage. This elevated mutation burden means R151C carriers who do develop melanoma carry more mutagenic hits, consistent with the mechanistic role of impaired DNA repair.

Non-melanoma skin cancer: The M-SKIP pooled analysis88 M-SKIP pooled analysis
Tagliabue et al. 2015, British Journal of Cancer; PMID 26103569 across multiple European studies found R151C associated with basal cell carcinoma (OR 1.86, 95% CI 1.35–2.56) and squamous cell carcinoma (OR 2.10, 95% CI 1.53–2.87), with R151C having the highest attributable risk of any MC1R variant (7.3% of BCC and 11.1% of SCC cases).

Red hair and sun sensitivity: In a GWAS of nearly 7,000 Icelanders and Dutch99 GWAS of nearly 7,000 Icelanders and Dutch
Sulem et al. 2007; PMID 17952075, R151C showed extraordinary association with red hair (OR 12.47, P=2.0×10⁻¹⁴²), sun sensitivity (OR 2.94), and freckling (OR 4.37), establishing it as the dominant genetic driver of the red hair/fair skin phenotype.

Practical Implications

The primary management goal for R151C carriers is skin cancer prevention and early detection. Since part of the risk operates through UV-independent oxidative pathways, sun protection alone is necessary but not sufficient — annual dermatology examinations are essential regardless of how much sun exposure you have had.

The vitamin D paradox: fair-skinned MC1R variant carriers historically evolved in low-UV environments where reduced eumelanin allowed efficient UVB-driven vitamin D synthesis. But behavioral sun avoidance — the correct response to elevated skin cancer risk — suppresses that synthesis. Monitoring 25-OH vitamin D levels and supplementing to maintain sufficiency (≥30 ng/mL) closes this gap without requiring UV exposure.

MC1R also affects anesthesia response. Redheads require ~19% more volatile anesthetic (desflurane, sevoflurane)1010 Redheads require ~19% more volatile anesthetic (desflurane, sevoflurane)
Liem et al. 2004; PMID 15277908 for adequate surgical depth, and local anesthetics (lidocaine) are also less effective. Inform any anesthesiologist or dentist of your MC1R status before procedures.

Interactions

The three high-penetrance MC1R variants — R151C (rs1805007), R160W (rs1805008), and D294H (rs1805009) — interact through compound heterozygosity. Carrying R151C on one chromosome and R160W on the other produces full loss of function, identical to being homozygous TT at any single site. Studies show that individuals carrying two R alleles (any combination) have approximately 4-fold elevated melanoma risk versus wild-type, compared to roughly 2-fold for a single R allele.

MC1R variants substantially amplify the penetrance of CDKN2A mutations (p16-Leiden). In families with heritable CDKN2A mutations, MC1R R alleles nearly doubled melanoma risk1111 MC1R R alleles nearly doubled melanoma risk
van der Velden et al. 2001; PMID 11500806 compared to CDKN2A carriers without MC1R variants. Individuals with a family history of melanoma and known CDKN2A pathogenic variants should disclose MC1R status to their genetic counselor, as the compound risk may warrant enhanced surveillance protocols.

SLC45A2 L374F (rs16891982) and MC1R R151C act through related but distinct pigmentation pathways; carrying both high-risk alleles compounds UV vulnerability. Individuals with melanoma-risk alleles at both loci are considered at substantially elevated risk and should be prioritized for intensive photoprotection and annual dermatology surveillance.

Proposed compound action for supervisor: Individuals carrying MC1R R151C (rs1805007 TT or CT) together with another R allele such as R160W (rs1805008 CT or TT) or D294H (rs1805009 CT or TT) face compound loss-of-function. The combined recommendation would be even more intensive sun protection, biannual dermatology screening (rather than annual), and 25-OH vitamin D monitoring — a distinctly stronger protocol than either variant alone.

Drug Interactions

desflurane dose_adjustment literature
sevoflurane dose_adjustment literature

Nutrient Interactions

vitamin D increased_need

Genotype Interpretations

What each possible genotype means for this variant.

CC Wild-Type MC1R Normal

Standard MC1R function with normal eumelanin production and baseline skin cancer risk

You carry two copies of the reference MC1R allele, meaning your melanocortin-1 receptor functions normally. When UV light triggers α-MSH signaling, your melanocytes can shift efficiently toward protective eumelanin production, giving your skin better natural UV defense than R151C carriers. About 87% of individuals of European descent share this genotype; it is even more prevalent in African and East Asian populations. Your baseline melanoma risk is not zero — sun behavior, total nevus count, and family history all matter — but you lack the elevated genetic predisposition conferred by R151C.

CT One R Allele Intermediate

Partial MC1R impairment; ~40% elevated melanoma risk and moderately reduced tanning capacity

The additive inheritance pattern means R151C confers a graded risk: one copy raises risk ~40%, two copies raise it ~2–4-fold. In the meta-analysis by Williams et al. (2011), CT heterozygotes had meaningfully elevated but intermediate risk compared to TT homozygotes. The elevation is real but smaller than for TT carriers. Some heterozygotes have clearly lighter coloring than CC individuals, particularly if the other allele is also low-activity. The practical implication is that CT carriers should adopt more rigorous sun protection than they might otherwise assume is necessary based on phenotype alone — your skin's UV defenses are genetically reduced even if you appear normally pigmented.

TT Homozygous R Allele High Risk

Nonfunctional MC1R; 2–4× elevated melanoma risk, doubled somatic mutation burden, and 19% higher anesthetic requirement

The TT genotype represents complete loss of MC1R eumelanin signaling. Every melanocyte in your body defaults to pheomelanin synthesis, which means sun-exposed and sun-protected skin alike experiences the downstream oxidative consequences of pheomelanin chemistry. Mouse melanoma experiments removing pheomelanin synthesis while keeping the MC1R null background completely suppressed melanoma development, demonstrating that pheomelanin itself — not just UV exposure — is mechanistically causal.

Beyond skin cancer, TT homozygotes demonstrate a well-documented anesthesia phenotype: requiring ~19% more desflurane and sevoflurane for surgical anesthesia, and showing reduced efficacy of local anesthetics (lidocaine) at standard doses. Women with TT or compound-heterozygous genotypes also show paradoxically enhanced response to kappa-opioid analgesics (pentazocine, nalbuphine). These anesthesia effects are pharmacogenetically distinct from the skin cancer effects and should be disclosed to all treating clinicians.

The cumulative skin cancer risk is meaningful across all skin cancer types: melanoma, basal cell carcinoma (OR ~2.3–3.7), and squamous cell carcinoma (OR ~2.6–4.4). Daily, consistent sun protection combined with annual dermatology surveillance is the evidence-based management approach. Vitamin D monitoring is important because adequate sun avoidance — the correct behavioral response to your risk — predictably suppresses cutaneous vitamin D synthesis.